Haemochromatosis

The Lancet

Volumn 388, Issue 10045, 2016, Pages 706-716

  Powell, Lawrie W ^a   Seckington, Rebecca C ^a   Deugnier, Yves ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENE; GENETIC SCREENING; GENETICS; GENOTYPE; HEMOCHROMATOSIS; HFE GENE; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER DISEASE; LONG TERM CARE; META ANALYSIS (TOPIC); MODIFIER GENE; ORGAN INJURY; PATHOPHYSIOLOGY; PATIENT CARE; PENETRANCE; PHENOTYPE; PHLEBOTOMY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; BLOOD; CAUCASIAN; DEFICIENCY; DISEASE MANAGEMENT; DRINKING BEHAVIOR; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; EUROPE; LIVER; LIVER DISEASES; MASS SCREENING; METABOLISM; MUTATION; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDS; UNCERTAINTY;

CATION TRANSPORT PROTEIN; FERRITIN; HEMOCHROMATOSIS PROTEIN; HEPCIDIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON; MEMBRANE PROTEIN; METAL TRANSPORTING PROTEIN 1; TFR2 PROTEIN, HUMAN; TRANSFERRIN RECEPTOR;

ALCOHOL DRINKING; CATION TRANSPORT PROTEINS; DISEASE MANAGEMENT; ENVIRONMENTAL EXPOSURE; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FERRITINS; GENETIC TESTING; GENOTYPE; HEMOCHROMATOSIS; HEMOCHROMATOSIS PROTEIN; HEPCIDINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; LIVER; LIVER DISEASES; MASS SCREENING; MEMBRANE PROTEINS; MUTATION; PHENOTYPE; PHLEBOTOMY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TRANSFERRIN; RISK FACTORS; SEX FACTORS; UNCERTAINTY;

EID: 84960411269     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01315-X     Document Type: Review

References (124)

1. 1 Merryweather-Clarke, AT, Worwood, M, Parkinson, L, et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 101 (1998), 369–373.
2. 2 Merryweather-Clarke, AT, Pointon, JJ, Shearman, JD, Robson, KJ, Global prevalence of putative haemochromatosis mutations. J Med Genet 34 (1997), 275–278.
3. 3 Bacon, BR, Powell, LW, Adams, PC, Kresina, TF, Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 116 (1999), 193–207.
4. 4 Whitlock, EP, Garlitz, BA, Harris, EL, Beil, TL, Smith, PR, Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med, 145, 2006, 209.
5. 5 Wood, MJ, Powell, LW, Ramm, GA, Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111 (2008), 4456–4462.
6. 6 Kasper, D, Fauci, A, Hauser, S, Longo, D, Jameson, L, Loscalzo, J, (eds.) Harrion's Principles of Internal Medicine, 19th edn., 2015, McGraw Hill Education, New York.
7. 7 Olynyk, JK, Trinder, D, Ramm, GA, Britton, RS, Bacon, BR, Hereditary hemochromatosis in the post-HFE era. Hepatology 48 (2008), 991–1001.
8. 8 Beutler, E, Felitti, VJ, Koziol, JA, Ho, NJ, Gelbart, T, Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002), 211–218.
9. 9 Nemeth, E, Ganz, T, The role of hepcidin in iron metabolism. Acta Haematol, 122, 2009, 78.
10. 10 Drakesmith, H, Schimanski, LM, Ormerod, E, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106 (2005), 1092–1097.
11. 11 Schimanski, LM, Drakesmith, H, Merryweather-Clarke, AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 105 (2005), 4096–4102.
12. 12 Kono, S, Aceruloplasminemia. Curr Drug Targets 13 (2012), 1190–1199.
13. 13 Miyajima, H, Aceruloplasminemia. Neuropathology 35 (2015), 83–90.
14. 14 Bacon, BR, Britton, RS, The pathology of hepatic iron overload: a free radical-mediated Process?. Hepatology 11 (1990), 127–137.
15. 15 Loréal, O, Deugnier, Y, Moirand, R, et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol, 16, 1992, 122.
16. 16 Fletcher, LM, Dixon, JL, Purdie, DM, Powell, LW, Crawford, DHG, Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology, 122, 2002, 281.
17. 17 European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 53 (2010), 3–22.
18. 18 Allen, KJ, Gurrin, LCP, Constantine, CCP, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358 (2008), 221–230.
19. 19 Deugnier, Y, Mosser, J, Modifying factors of the HFE hemochromatosis phenotype. Expert Rev Gastroenterol Hepatol 2 (2008), 531–540.
20. 20 Jackson, HA, Carter, K, Darke, C, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 114 (2001), 474–484.
21. 21 Adams, PC, Reboussin, DM, Barton, JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 (2005), 1769–1778.
22. 22 Jacolot, S, Le Gac, G, Scotet, V, Quere, I, Mura, C, Ferec, C, HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 103 (2004), 2835–2840.
23. 23 Le Gac, G, Scotet, V, Ka, C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 13 (2004), 1913–1918.
24. 24 Van Vlierberghe, H, Langlois, M, Delanghe, J, et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 35 (2001), 707–711.
25. 25 Milet, J, Déhais, V, Bourgain, C, Jouanolle, AM, Common variants in the BMP2, BMP4, and HJV genes of the hepeidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet, 81, 2007, 799.
26. 26 Milet, J, Le Gac, G, Scotet, V, et al. A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: a follow-up study. Blood Cells Mol Dis 44 (2010), 34–37.
27. 27 Benyamin, B, McRae, AF, Zhu, G, Variants in TF and HFE explain ∼40% of genetic variation in serum-transferrin levels. Am J Hum Genet, 84, 2009, 60.
28. 28 de Tayrac, M, Roth, M-P, Jouanolle, A-M, et al. Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis. J Hepatol 62 (2015), 664–672.
29. 29 Benyamin, B, Esko, T, Ried, JS, Radhakrishnan, A, Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun, 5, 2014, 4926.
30. 30 Stickel, F, Buch, S, Zoller, H, et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet, 23, 2014, 3883.
31. 31 Pelucchi, S, Mariani, R, Calza, S, et al. CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica 97 (2012), 1818–1825.
32. 32 McLaren, CE, Emond, MJ, Subramaniam, VN, et al. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload. Hepatology 62 (2015), 429–439.
33. 33 Besson-Fournier, C, Martinez, M, Vinel, JP, Aguilar-Martinez, P, Coppin, H, Roth, MP, Further support for the association of GNPAT variant rs11558492 with severe iron overload in hemochromatosis. Hepatology, 2015, 10.1002/hep.28259 published online Sept 29.
34. 34 Ryan, E, Russel, J, Ryan, J, Crowe, J, Stewart, S, GNPAT variant is not associated with severe iron overload in Irish C282Y homozygotes. Hepatology, 2015, 10.1002/hep.28258 published online Sept 29.
35. 35 Bardou-Jacquet, E, de Tayrac, M, Mosser, J, Deugnier, Y, GNPAT variant associated with severe iron overload in HFE hemochromatosis. Hepatology 62 (2015), 1917–1918.
36. 36 Barton, JC, Barton, JC, Acton, RT, Longer survival associated with HLA-A*03, B*14 among 212 hemochromatosis probands with HFE C282Y homozygosity and HLA-A and -B typing and haplotyping. Eur J Haematol 85 (2010), 439–447.
37. 37 Aguilar-Martinez, P, Bismuth, M, Blanc, F, et al. The southern French registry of genetic hemochromatosis: a tool for determining clinical prevalence of the disorder and genotype penetrance. Haematologica 95 (2010), 551–556.
38. 38 Shimizu, I, Impact of oestrogens on the progression of liver disease. Liver Int 23 (2003), 63–69.
39. 39 Cade, JE, Moreton, JA, O'Hara, B, et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr 82 (2005), 813–820.
40. 40 Tsukamoto, H, Horne, W, Kamimura, S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 96 (1995), 620–630.
41. 41 Scotet, V, Mérour, M-C, Mercier, A-Y, et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol 158 (2003), 129–134.
42. 42 Adams, PC, Agnew, S, Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 23 (1996), 724–727.
43. 43 Powell, EE, Ali, A, Clouston, AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 129 (2005), 1937–1943.
44. 44 Diwakaran, HH, Befeler, AS, Britton, RS, Brunt, EM, Bacon, BR, Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 36 (2002), 687–691.
45. 45 Milward, EA, Baines, SK, Knuiman, MW, et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc 83 (2008), 543–549.
46. 46 Gurrin, LC, Bertalli, NA, Dalton, GW, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 50 (2009), 94–101.
47. 47 Wallace, DF, Dooley, JS, Walker, AP, A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology, 116, 1999, 1409.
48. 48 Piperno, A, Arosio, C, Fossati, L, et al. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 119 (2000), 441–445.
49. 49 O'Neil, J, Powell, LW, Clinical aspects of hemochromatosis. Semin Liver Dis 25 (2005), 381–391.
50. 50 Fracanzani, AL, Piperno, A, Valenti, L, et al. Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 51 (2010), 501–510.
51. 51 Yamashita, C, Adams, PC, Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol, 1, 2003, 388.
52. 52 Åsberg, A, Hveem, K, Krüger, Ø, Bjerve, KS, Persons with screening-detected haemochromatosis: as healthy as the general population?. Scandi J Gastroenterol 37 (2002), 719–724.
53. 53 Andersen, RV, Tybjaerg-Hansen, A, Appleyard, M, Birgens, H, Nordestgaard, BG, Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103 (2004), 2914–2919.
54. 54 Olynyk, JK, Hagan, SE, Cullen, DJ, Beilby, J, Whittall, DE, Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 79 (2004), 309–313.
55. 55 Gurrin, LC, Osborne, NJ, Constantine, CC, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 135 (2008), 1945–1952.
56. 56 Sahinbegovic, E, Dallos, T, Aigner, E, et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum, 62, 2010, 3792.
57. 57 Guggenbuhl, P, Brissot, P, Loreal, O, Haemochromatosis: the bone and the joint. Best Pract Res Clin Rheumatol 25 (2011), 649–664.
58. 58 Richette, P, Ottaviani, S, Vicaut, E, Bardin, T, Musculoskeletal complications of hereditary hemochromatosis: a case-control study. J Rheumatol 37 (2010), 2145–2150.
59. 59 Sinigaglia, L, Fargion, S, Fracanzani, AL, et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol, 24, 1997, 1809.
60. 60 Guggenbuhl, P, Deugnier, Y, Boisdet, JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16 (2005), 1809–1814.
61. 61 Valenti, L, Varenna, M, Fracanzani, AL, Rossi, V, Fargion, S, Sinigaglia, L, Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20 (2009), 549–555.
62. 62 Eyres, KS, McCloskey, EV, Fern, ED, et al. Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone 13 (1992), 431–433.
63. 63 Duquenne, M, Rohmer, V, Legrand, E, Chappard, D, Spontaneous multiple vertebral fractures revealed primary haemochromatosis. Osteoporos Int, 6, 1996, 338.
64. 64 Deugnier, Y, Jouanolle, A-M, Chaperon, J, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 118 (2002), 1170–1178.
65. 65 Acton, RT, Barton, JC, Passmore, LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the hemochromatosis and iron overload screening (HEIRS) study. Diabetes Care 29 (2006), 2084–2089.
66. 66 Åsberg, A, Hveem, K, Thorstensen, K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scandi J Gastroenterol 36 (2001), 1108–1115.
67. 67 Adams, P, Brissot, P, Powell, LW, EASL International consensus conference on haemochromatosis. J Hepatol 33 (2000), 487–496.
68. 68 Powell, L, Powell, LW, Dixon, JL, Hewett, DG, Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Rheumatol 18 (2005), 221–234.
69. 69 Rochette, J, Le Gac, G, Lassoued, K, Férec, C, Robson, KJH, Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum Genet 128 (2010), 233–248.
70. 70 Fletcher, L, Halliday, J, Powell, L, Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol 14 (1999), 202–214.
71. 71 Whitfield, JB, Zhu, G, Heath, AC, Powell, LW, Martin, NG, Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res 25 (2001), 1037–1045.
72. 72 McLaren, CE, McLachlan, GJ, Halliday, JW, et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology, 114, 1998, 543.
73. 73 Olynyk, JKMD, Cullen, DJMBBS, Aquilia, SBA, Rossi, EP, Summerville, LB, Powell, LWMDP, A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341 (1999), 718–724.
74. 74 Powell, LW, Dixon, JL, Ramm, GA, Purdie, DM, Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 166 (2006), 294–301.
75. 75 Gan, EK, Powell, LW, Olynyk, JK, Natural history and management of HFE-hemochromatosis. Semin Liver Dis 31 (2011), 293–301.
76. 76 Adams, PC, Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet 53 (1998), 176–178.
77. 77 Delatycki, MB, Powell, LW, Allen, KJ, Hereditary hemochromatosis genetic testing of at-risk children: what is the appropriate age?. Genet Test 8 (2004), 98–103.
78. 78 Bacon, BR, Adams, PC, Kowdley, KV, Powell, LW, Tavill, AS, Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54 (2011), 328–343.
79. 79 Adams, PC, Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med, 120, 2007, 999.
80. 80 Guyader, D, Jacquelinet, C, Moirand, R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology, 115, 1998, 929.
81. 81 Crawford, DHG, Murphy, TL, Ramm, LE, et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 49 (2009), 418–425.
82. 82 Legros, L, Bardou-Jacquet, E, Latournerie, M, et al. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int 35 (2015), 1731–1738.
83. 83 Stuart, KA, Stuart, KA, Busfield, F, Jazwinska, EC, Gibson, P, The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 28 (1998), 404–409.
84. 84 Ajioka, RS, Phillips, JD, Weiss, RB, et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 112 (2008), 4723–4728.
85. 85 George, DK, Goldwurm, S, MacDonald, GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 114, 1998, 311.
86. 86 Bonkovsky, HL, Jawaid, Q, Tortorelli, K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31 (1999), 421–429.
87. 87 Franchini, M, Targher, G, Capra, F, Montagnana, M, Lippi, G, The effect of iron depletion on chronic hepatitis C virus infection. Hepatol Int 2 (2008), 335–340.
88. 88 Costa-Matos, L, Batista, P, Monteiro, N, Henriques, P, Girao, F, Carvalho, A, HFE mutations and iron overload in patients with alcoholic liver disease. Arq Gastroenterol, 50, 2013, 35.
89. 89 Deugnier, Y, Turlin, B, le Quilleuc, D, et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol 21 (1997), 669–675.
90. 90 Cotler, SJ, Cotler, SJ, Bronner, MP, Press, RD, Carlson, TH, End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 29 (1998), 257–262.
91. 91 Ludwig, J, Hashimoto, E, Porayko, MK, Moyer, TP, Baldus, WP, Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology, 112, 1997, 882.
92. 92 Bridle, KR, Cheung, T-K, Murphy, TL, et al. Hepcidin is down-regulated in alcoholic liver injury: Implications for the Pathogenesis of Alcoholic Liver Disease. Alcohol Clin Exp Res 30 (2006), 106–112.
93. 93 Harrison-Findik, DD, Schafer, D, Klein, E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281 (2006), 22974–22982.
94. 94 Harrison-Findik, DD, Klein, E, Crist, C, Evans, J, Timchenko, N, Gollan, J, Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 46 (2007), 1979–1985.
95. 95 Osborne, NJ, Gurrin, LC, Allen, KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 51 (2010), 1311–1318.
96. 96 Niederau, C, Fischer, R, Pürschel, A, Stremmel, W, Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996), 1107–1119.
97. 97 Adams, PC, Speechley, M, Kertesz, AE, Long-term survival analysis in hereditary hemochromatosis. Gastroenterology, 101, 1991, 368.
98. 98 Bismuth, M, Peynaud-Debayle, E, Prise en charge de l'hémochromatose liée au gene HFE (hémochromatose de type 1): Haute Autorité de Santé (HAS). http://www.has-sante.fr/portail/jcms/c_432802/fr/prise-en-charge-de-l-hemochromatose-liee-au-gene-hfe-hemochromatose-de-type-1, 2005 (accessed Aug 31, 2015).
99. 99 Raymakers, RAP, Raymakers, RAP, Swinkels, DW, Jorna, AT, Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med 65 (2007), 452–455.
100. 100 Barton, JC, McDonnell, SM, Adams, PC, et al. Management of hemochromatosis. hemochromatosis management working group. Ann Intern Med, 129, 1998, 932.
101. 101 Falize, L, Guillygomarc'h, A, Perrin, M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44 (2006), 472–477.
102. 102 Desmet, VJ, Roskams, T, Cirrhosis reversal: a duel between dogma and myth. J Hepatol 40 (2004), 860–867.
103. 103 Desmet, VJ, Desmet, VJ, Comments on cirrhosis reversal. Dig Liver Dis 37 (2005), 909–916.
104. 104 Niederau, C, Fischer, R, Sonnenberg, A, Stremmel, W, Trampisch, HJ, Strohmeyer, G, Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313 (1985), 1256–1262.
105. 105 Waalen, J, Nordestgaard, BG, Beutler, E, The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 18 (2005), 203–220.
106. 106 Bardou-Jacquet, E, Morcet, J, Manet, G, et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol 62 (2015), 682–689.
107. 107 Delatycki, MB, Gurrin, LC, Ong, SY, et al. Reduced mortality due to phlebotomy in moderately iron-loaded HFE haemochromatosis? The need for clinical trials. J Hepatol 63 (2015), 282–283.
108. 108 Ong, SY, Dolling, L, Dixon, JL, et al. Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). BMJ Open, 5, 2015, e008938.
109. 109 Phatak, P, Brissot, P, Wurster, M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology, 52, 2010, 1671.
110. 110 Stefashyna, O, Stefashyna, O, Stern, M, Infanti, L, Holbro, A, Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre. Vox Sang 106 (2014), 111–117.
111. 111 Brissot, P, Troadec, M-B, Bardou-Jacquet, E, et al. Current approach to hemochromatosis. Blood Rev 22 (2008), 195–210.
112. 112 Loréal, O, Turlin, B, Pigeon, C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 36 (2002), 851–856.
113. 113 Moretti, D, van Doorn, GM, Swinkels, DW, Melse-Boonstra, A, Relevance of dietary iron intake and bioavailability in the management of HFE hemochromatosis: a systematic review. Am J Clin Nutr 98 (2013), 468–479.
114. 114 Kaltwasser, JP, Werner, E, Schalk, K, Hansen, C, Gottschalk, R, Seidl, C, Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43 (1998), 699–704.
115. 115 Nienhuis, AW, Vitamin C and iron. N Engl J Med 304 (1981), 170–171.
116. 116 Crawford, DHG, Fletcher, LM, Hubscher, SG, et al. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 39 (2004), 1655–1662.
117. 117 Yu, L, Ioannou, GN, Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 133 (2007), 489–495.
118. 118 Powell, LW, Dixon, JL, Ramm, GA, Purdie, DM, Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med, 166, 2006, 294.
119. 119 Kowdley, KV, Hassanein, T, Kaur, S, et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transplant Surg 1 (1995), 237–241.
120. 120 Kowdley, KV, Brandhagen, DJ, Gish, RG, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 129 (2005), 494–503.
121. 121 Dar, FS, Faraj, W, Zaman, MB, et al. Outcome of liver transplantation in hereditary hemochromatosis. Transpl Int, 22, 2009, 717.
122. 122 Bardou-Jacquet, E, Philip, J, Lorho, R, et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 59 (2014), 839–847.
123. 123 Gandon, Y, Olivié, D, Guyader, D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363 (2004), 357–362.
124. 124 Guyader, D, Gandon, Y, Sapey, T, Turlin, B, Magnetic resonance iron-free nodules in genetic hemochromatosis. Am J Gastroenterol 94 (1999), 1083–1086.